Matt Carr: Psychedelics Paving a New Age for Medicine

TL;DR

Psychedelic medicine is a nascent market with significant growth potential, similar to the early days of the cannabis industry, and is expected to be a $100 billion global market by 2030.

Transcript

for the investing news network i am brian mcgovern with me today to discuss psychedelic investments is madcar chief trans strategist at the oxford club matt i really appreciate your time today always my pleasure to be here thanks fred why don't you start with your impressions on the factors so far we're about one year removed from my med hitting th... Read More

Key Insights

• 🎁 Psychedelic medicine presents a significant investment opportunity similar to the early days of the cannabis industry.
• 🤑 The market has a rich history of human consumption and is now being recognized for its medical benefits.
• #️⃣ The limited number of companies in the sector provides an opportunity for investors to get involved early.
• 🥺 Companies like Compass Pathways and MindMed are leading the way in psychedelic medicine.
• ❓ Medicinal legalization is a crucial catalyst for market growth.
• 💊 Psychedelic medicine has significant potential in treating conditions like depression, anxiety, PTSD, and addiction.
• 👨‍🔬 Research institutes, such as Johns Hopkins, are investing in psychedelic medicine research, aiding its growth.

Questions & Answers

Q: What makes psychedelic medicine an interesting investment opportunity?

Psychedelic medicine is an emerging market with significant growth potential, similar to the early stages of the cannabis industry. It has a rich history of human consumption and is now being recognized for its medical benefits, driving the market's growth.

Q: How does the psychedelic medicine market compare to the cannabis market?

Both markets initially gained traction through medical legalization. Psychedelic medicine is currently at an early stage with a limited number of companies, making it an appealing investment opportunity. The medicinal market for both cannabis and psychedelic medicine is expected to surpass the recreational market in the long run.

Q: How can investors differentiate between psychedelic medicine companies?

Since many psychedelic medicine companies are at the biotech stage, investors should focus on clear pathways for treatments and the potential market size for specific conditions. Companies like Compass Pathways have received FDA breakthrough therapy designation, giving them an edge in the market.

Q: What catalysts can trigger momentum and awareness for the psychedelic medicine sector?

State-based legalization victories, similar to those seen in the cannabis industry, can trigger momentum and increased acceptance of psychedelic medicine. As more states legalize its use, public sentiment and awareness are likely to grow.

Summary & Key Takeaways

• Psychedelic medicine is an emerging industry similar to the early days of the cannabis market, presenting an exciting investment opportunity.

• Human history has shown the use of psychedelics for spiritual and recreational purposes, but recent research has revealed their potential for medical benefits, particularly in treating conditions like depression.

• The number of players in the psychedelic medicine market is currently limited, presenting an opportunity for investors. Companies like Compass Pathways and MindMed are leading the way in this sector.